Abstract
Objectives: To examine the pharmacokinetics of danaparoid sodium in patients undergoing continuous hemodiafiltration (CHDF). Methods: Six patients requiring CHDF with acute-disseminated intravascular coagulation (DIC) score above 4 points were enrolled in this study at Gifu Prefectural Tajimi Hospital between 2002 and 2005. They received a single i.v. injection of danaparoid sodium 1,250 units (1 ml). Anti-activated factor X activity (anti-Xa activity) in plasma was measured at 8 time points (before i.v. injection and 0.5, 2, 4 , 8 , 12 , 24, and 48 hours after i.v. injection). Results: Derived time-concentration data were analyzed pharmacokinetically using a two-compartment model, and elimination half life was estimated. Mean half-life of anti-Xa activity in plasma in the 6 patients was 27.1 hours, and about twice that in normal individuals (14.3 hours). However, mean anti-Xa activity in plasma returned to pre-injection level by 48 hours after i.v. injection. Conclusions: Our findings suggest that danaparoid sodium may be safely given to patients undergoing CHDF with consideration given to dosing interval. Further detailed studies of a large number of patients are needed to more clearly determine the pharmacokinetic characteristics of danaparoid sodium.
